Clinical Trials on Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

Total 1330 results

OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Epithelial Cancer | Stage IIIB Breast Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Southwest Oncology Group

Completed

Lung-MAP S1400K: c-MET Positive

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC V7

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
VA Office of Research and Development
VA Palo Alto Health Care System; VA Puget Sound Health Care System; Michael E... and other collaborators

Not yet recruiting

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Recurrent Bladder Carcinoma | Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Metastatic Transitional Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Neuroendocrine Carcinoma | Small Cell Carcinoma | Extensive Stage Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Large Cell Lung Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
University of Colorado, Denver

Active, not recruiting

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Novartis

Withdrawn

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

Recurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Metastatic Squamous Neck Cancer With Occult Primary | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Tongue Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditions

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI); Eli Lilly and Company; OSI Pharmaceuticals

Completed

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Terminated

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Terminated

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Recurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma

United States
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Completed

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Endometrial Papillary Serous Carcinoma

Canada
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
University of Washington
National Cancer Institute (NCI)

Completed

L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer

Mucositis | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma... and other conditions

United States
National Institutes of Health Clinical Center (CC)

Completed

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | MET Positive

United States
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada

Clinical Trials on Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations